What brand managers need to know to achieve data security maturity
Express Scripts warned of building an anti-Sovaldi coalition. If payers are unwilling to pay for such drugs, or band against their makers, where does pharma go from here?
Nine things CMOs should consider when desiring to engage consumers who no longer want to give their attention to boring and scripted product descriptions.
Are today's young adults on their way to healthier lives in middle age and beyond? New data from GfK's Roper Diabetes study series gives cause for concern.
More credit ought to be given to the investments and inventions made by the biopharmaceutical sector—no question. But placing responsibility on the media for a perceived lack of fairness seems misplaced.
With enrollment having just reached five million in a push to the March 31 deadline, the ACA is poised to turn the corner of public opinion.
Why I left SXSW this past week feeling like I just might live forever
Healthcare companies are partnering with social entrepreneurs to drive their own agendas on affordability and access while staying at the forefront of global initiatives
Incentives aren't the only reason orphan drugs are a success. More important are the lessons companies have learned about patients, social media and support.
Being decoded helps harness technology to bring out the best in people, attract talent and, ultimately, improve customer service, say authors of a new book
A rundown of the big trends in devices & diagnostics in 2014, based on research and analysis, and the growth opportunities they will provide
What it would be like to advertise treatment for earwax impaction, hypersalivation and gas during the big game.
Looking past all the noise, beleaguered portal offers pointed lessons to healthcare website developers
Looking beyond the plethora of fitness trackers on display at CES 2014, one can glean which consumer trends are likely to impact the future of pharma marketing—Are you ready for the Internet of Things?
For this romance between two unlikely partners to work, Pharma must let go of its idea of a traditional sales force.
A patient panel provides a prescription for pharma social media success
How pharma can integrate mobile & social in 2014
Fundamental flaws in our current business model must be fixed if our industry is to stay vital and competitive into the next decade.
Getting to an integrated mar-comms model isn't easy. Addressing your agency's lack of digital skills is a good start.
All decisions have an emotional component. Even those, like technology, where we think reason has won the day.
The ad push around "Low T," and ongoing industry criticism, is a reminder to advertise responsibly.
Cultivating relationships digitally is a long-term play. Yet few pharma campaigns are set up for that kind of promotion
Will J&J ever regain its once stellar reputation for ethics and social responsibility?
Remember when it felt good to say you worked in pharma? How to get the people who benefit from our products to recognize and articulate the value they receive
In schizophrenia, non-compliance can be disastrous. Do depot drugs really make a difference for patients?
Why agencies must get out of the strategy business.
The Wizards of White Oak are spending $10 million on DTC ad research. Is this a wise use of sparse agency resources?
ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.
It is often hard to find the right words when talking to a patient, friend or family member with MS. Even with training and awareness of the disease, we often blurt out something we think is innocuous only to find out later that we have deeply offended. The Health Activists that Extrovertic spoke to had some suggestions for having positive conversations with someone with MS.
Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.
India, a nation known for its innovation in many areas, has decided that incremental innovation in pharmaceuticals isn't important—at least when it comes to patent protection
Healthcare is moving from its traditional two places for delivery—the hospital and the doctor's office—to the patient, aided in part by mobile devices and always-on connectivity.
Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.
A relative's illness challenges a pharma consultant's view of industry progress.
What the agency writes in a recent warning letter to a dietary supplement firm is instructive with regard to "Liking" off-label posts.
When Hollywood shines its spotlight on your industry, you never know how you're going to be portrayed. In "Side Effects," the view is less than flattering.
At a time when some regulatory bodies and biopharma companies are increasing their transparency initiatives involving access to clinical-trial data, disclosing trial results to volunteers could also go a long way toward strengthening public confidence.
The deadly meningitis outbreak highlights the threat not only to public health, but also to the pharma industry, posed by the largely unregulated practice of pharmacy compounding.
Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
FDA's recent draft guidance on off-label communication is, despite its shortcomings, a step forward, writes John Kamp, arguing that pharmas should take this welcome bit of clarity and act boldly on it
FDA's first draft guidance to come out of its 2009 online communication hearing offers sound counsel but not much in the way of specifics, writes Peter Pitts. The takeaway: where the letter of the law is hazy, exercise your judgement and follow, as best you can, the spirit of the law.
The pace of adoption of the iPad continues to startle, and already half of the top 20 pharma companies have bought into the tablet platform. But now comes the tricky part: how will pharma actually use their fancy new machines? Bill Drummy reports.